

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

NCT07500220

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Beijing Biotech
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (13)

- Age 18 to 75 years.
- Histologically or cytologically confirmed HCC, or radiologically diagnosed HCC with mandatory tissue confirmation of target expression before enrollment.
- Unresectable, locally advanced, or metastatic HCC not amenable to curative surgery, transplant, or further locoregional therapy; BCLC stage C, or stage B that is not suitable for or has progressed after locoregional therapy.
- Disease progression on, intolerance to, or ineligibility for at least 1 prior standard systemic regimen.
- Central pathology showing GPC3 positivity in $\geq 25\%$ of viable tumor cells by IHC and B7-H3 positivity in $\geq 10\%$ of tumor cells and/or tumor-associated stromal/vascular cells by IHC.

... and 8 more (see full listing online)

Exclusion (12)

- Prior gene-modified cellular therapy (for example prior CAR-T, CAR-NK, or TCR-engineered therapy) within the protocol-defined washout period or with unresolved clinically significant toxicity.
- Active, uncontrolled infection, including uncontrolled bacterial, viral, or fungal infection; uncontrolled HIV; active HBV or HCV with uncontrolled viral load; or active tuberculosis.
- Known active CNS metastases or leptomeningeal disease requiring escalating steroids or urgent local intervention.
- Liver transplant or other solid-organ transplant history, or current requirement for chronic immunosuppression.
- Clinically significant ascites requiring frequent drainage, grade ≥ 2 hepatic encephalopathy within 4 weeks, or recent clinically significant variceal/GI bleeding.

... and 7 more (see full listing online)

Locations (1 total)

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China